According to The Guardian Japanese flu drug is an effective solution for COVID-19 treatment
An auspicious COVID-19 drugs
Yesterday, 18.03.2020, there was suggested, that «Favipiravir», developed by Fujifilm group, is effective in slowing the virus-infected cells transmitting process and, as a result, provides complete cure in only 4 days.
The drug has become a real sensation in the media after the information, introduced by Zhang Xinmin, an official at China’s science and technology ministry. Xinmin stated, that an experimental Favipiravir treatment, involving 340 patients, had produced encouraging outcomes in clinical trials in Wuhan and Shenzhen. Patients, who were given the medicine, turned negative for the virus in four days of treatment, comparing to those, who were not treated with the drug, and showed the same results in 11 days, not to mention, that X-rays confirmed improvements in lung condition in about 91% of patients, taking Favipiravir.
What about the treatment for COVID-19 in Japan?
The clinical practice of treating mild to moderate symptomatic forms of coronavirus in Japan is also based on using Favipiravir, also known as Avigan. Prevention measures and properly selected therapeutic systems using this drug effectively block RNA transcription of coronavirus in healthy body cells.
However, the Ministry of Health of Japan suggested Avigan was not as effective in treating people with more severe symptoms.
Accordint to Mainichi Shimbun, the effect of Avigan treatment of 80 patients with decreased lung function and the other complications, wasn’t that successful. Moreover, some limitations had been identified using Avigan in a combination of antiretrovirals Lopinavir and Ritonavir.
In 2016, Avigan was supplied by the Japanese government to counter the Ebola virus outbreak in Guinea. Nevertheless, Mainichi Shimbun claims this exact drug to be approved by the government for full-scale use on COVID-19 patients, since it was initially created for flu treatment.
Additional info on Covid-19 struggle
Recently, Dutch scientists discovered the specific antibody that blocks the synthesis of the components of COVID-19 and its interaction with a cell.
The National Institute of Allergy and Infectious Disease reports, that on March 17, 2020, the first four volunteers introduced the vaccine for COVID-19 in the US, which had been developed in record time.